47 results on '"Reese, Jens-Peter"'
Search Results
2. A precise performance-based reimbursement model for the multi-centre NAPKON cohorts – development and evaluation.
- Author
-
Appel, Katharina S., Lee, Chin Huang, Nunes de Miranda, Susana M., Maier, Daniel, Reese, Jens-Peter, Anton, Gabriele, Bahmer, Thomas, Ballhausen, Sabrina, Balzuweit, Beate, Bellinghausen, Carla, Blumentritt, Arne, Brechtel, Markus, Chaplinskaya-Sobol, Irina, Erber, Johanna, Fiedler, Karin, Geisler, Ramsia, Heyder, Ralf, Illig, Thomas, Kohls, Mirjam, and Kollek, Jenny
- Abstract
Fair allocation of funding in multi-centre clinical studies is challenging. Models commonly used in Germany - the case fees (“fixed-rate model”, FRM) and up-front staffing and consumables (“up-front allocation model”, UFAM) lack transparency and fail to suitably accommodate variations in centre performance. We developed a performance-based reimbursement model (PBRM) with automated calculation of conducted activities and applied it to the cohorts of the National Pandemic Cohort Network (NAPKON) within the Network of University Medicine (NUM). The study protocol activities, which were derived from data management systems, underwent validation through standardized quality checks by multiple stakeholders. The PBRM output (first funding period) was compared among centres and cohorts, and the cost-efficiency of the models was evaluated. Cases per centre varied from one to 164. The mean case reimbursement differed among the cohorts (1173.21€ [95% CI 645.68–1700.73] to 3863.43€ [95% CI 1468.89–6257.96]) and centres and mostly fell short of the expected amount. Model comparisons revealed higher cost-efficiency of the PBRM compared to FRM and UFAM, especially for low recruitment outliers. In conclusion, we have developed a reimbursement model that is transparent, accurate, and flexible. In multi-centre collaborations where heterogeneity between centres is expected, a PBRM could be used as a model to address performance discrepancies. Trial registration: ; ; . [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. A multicenter, matched case–control analysis comparing burden of illness among patients with tuberous sclerosis complex related epilepsy, generalized idiopathic epilepsy, and focal epilepsy in Germany.
- Author
-
Lappe, Lisa, Hertzberg, Christoph, Knake, Susanne, Knuf, Markus, von Podewils, Felix, Willems, Laurent M., Kovac, Stjepana, Zöllner, Johann Philipp, Sauter, Matthias, Kurlemann, Gerhard, Mayer, Thomas, Bertsche, Astrid, Marquard, Klaus, Meyer, Sascha, Schäfer, Hannah, Thiels, Charlotte, Zukunft, Bianca, Schubert-Bast, Susanne, Reese, Jens-Peter, and Rosenow, Felix
- Subjects
TUBEROUS sclerosis ,PARTIAL epilepsy ,IDIOPATHIC diseases ,REPORT cards ,EPILEPSY - Abstract
Background: Depending on the underlying etiology and epilepsy type, the burden of disease for patients with seizures can vary significantly. This analysis aimed to compare direct and indirect costs and quality of life (QoL) among adults with tuberous sclerosis complex (TSC) related with epilepsy, idiopathic generalized epilepsy (IGE), and focal epilepsy (FE) in Germany. Methods: Questionnaire responses from 92 patients with TSC and epilepsy were matched by age and gender, with responses from 92 patients with IGE and 92 patients with FE collected in independent studies. Comparisons were made across the main QoL components, direct costs (patient visits, medication usage, medical equipment, diagnostic procedures, ancillary treatments, and transport costs), indirect costs (employment, reduced working hours, missed days), and care level costs. Results: Across all three cohorts, mean total direct costs (TSC: €7602 [median €2620]; IGE: €1919 [median €446], P < 0.001; FE: €2598 [median €892], P < 0.001) and mean total indirect costs due to lost productivity over 3 months (TSC: €7185 [median €11,925]; IGE: €3599 [median €0], P < 0.001; FE: €5082 [median €2981], P = 0.03) were highest among patients with TSC. The proportion of patients with TSC who were unemployed (60%) was significantly larger than the proportions of patients with IGE (23%, P < 0.001) or FE (34%, P = P < 0.001) who were unemployed. Index scores for the EuroQuol Scale with 5 dimensions and 3 levels were significantly lower for patients with TSC (time-trade-off [TTO]: 0.705, visual analog scale [VAS]: 0.577) than for patients with IGE (TTO: 0.897, VAS: 0.813; P < 0.001) or FE (TTO: 0.879, VAS: 0.769; P < 0.001). Revised Epilepsy Stigma Scale scores were also significantly higher for patients with TSC (3.97) than for patients with IGE (1.48, P < 0.001) or FE (2.45, P < 0.001). Overall Quality of Life in Epilepsy Inventory-31 items scores was significantly lower among patients with TSC (57.7) and FE (57.6) than among patients with IGE (66.6, P = 0.004 in both comparisons). Significant differences between patients with TSC and IGE were also determined for Neurological Disorder Depression Inventory for Epilepsy (TSC: 13.1; IGE: 11.2, P = 0.009) and Liverpool Adverse Events Profile scores (TSC: 42.7; IGE: 37.5, P = 0.017) with higher score and worse results for TSC patients in both questionnaires. Conclusions: This study is the first to compare patients with TSC, IGE, and FE in Germany and underlines the excessive QoL burden and both direct and indirect cost burdens experienced by patients with TSC. Key points: • This is the first analysis to compare QoL and direct/indirect cost burden among patients with TSC, IGE, and FE in Germany. • Generic QoL for patients with TSC was significantly lower than for patients with IGE and FE. • Care grade and disability cards were more frequently obtained by patients with TSC than by patients in the other cohorts. • Drug treatment costs were the highest direct cost component for patients with TSC. • More patients with TSC than with IGE or FE were unemployed, and the mean indirect productivity costs were highest for the TSC cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort.
- Author
-
Shi, Yanyan, Strobl, Ralf, Apfelbacher, Christian, Bahmer, Thomas, Geisler, Ramsia, Heuschmann, Peter, Horn, Anna, Hoven, Hanno, Keil, Thomas, Krawczak, Michael, Krist, Lilian, Lemhöfer, Christina, Lieb, Wolfgang, Lorenz-Depiereux, Bettina, Mikolajczyk, Rafael, Montellano, Felipe A., Reese, Jens Peter, Schreiber, Stefan, Skoetz, Nicole, and Störk, Stefan
- Subjects
COVID-19 ,CONFIDENCE intervals ,TIME ,LOG-rank test ,RETROSPECTIVE studies ,SURVEYS ,RESEARCH funding ,SURVIVAL analysis (Biometry) ,KAPLAN-Meier estimator ,LONGITUDINAL method ,PROPORTIONAL hazards models ,PSYCHOLOGICAL resilience - Abstract
Purpose: We aimed to assess symptoms in patients after SARS-CoV-2 infection and to identify factors predicting prolonged time to symptom-free. Methods: COVIDOM/NAPKON-POP is a population-based prospective cohort of adults whose first on-site visits were scheduled ≥ 6 months after a positive SARS-CoV-2 PCR test. Retrospective data including self-reported symptoms and time to symptom-free were collected during the survey before a site visit. In the survival analyses, being symptom-free served as the event and time to be symptom-free as the time variable. Data were visualized with Kaplan–Meier curves, differences were tested with log-rank tests. A stratified Cox proportional hazard model was used to estimate adjusted hazard ratios (aHRs) of predictors, with aHR < 1 indicating a longer time to symptom-free. Results: Of 1175 symptomatic participants included in the present analysis, 636 (54.1%) reported persistent symptoms after 280 days (SD 68) post infection. 25% of participants were free from symptoms after 18 days [quartiles: 14, 21]. Factors associated with prolonged time to symptom-free were age 49–59 years compared to < 49 years (aHR 0.70, 95% CI 0.56–0.87), female sex (aHR 0.78, 95% CI 0.65–0.93), lower educational level (aHR 0.77, 95% CI 0.64–0.93), living with a partner (aHR 0.81, 95% CI 0.66–0.99), low resilience (aHR 0.65, 95% CI 0.47–0.90), steroid treatment (aHR 0.22, 95% CI 0.05–0.90) and no medication (aHR 0.74, 95% CI 0.62–0.89) during acute infection. Conclusion: In the studied population, COVID-19 symptoms had resolved in one-quarter of participants within 18 days, and in 34.5% within 28 days. Over half of the participants reported COVID-19-related symptoms 9 months after infection. Symptom persistence was predominantly determined by participant's characteristics that are difficult to modify. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Ethical and coordinative challenges in setting up a national cohort study during the COVID-19 pandemic in Germany.
- Author
-
Tilch, Katharina, Hopff, Sina M., Appel, Katharina, Kraus, Monika, Lorenz-Depiereux, Bettina, Pilgram, Lisa, Anton, Gabi, Berger, Sarah, Geisler, Ramsia, Haas, Kirsten, Illig, Thomas, Krefting, Dagmar, Lorbeer, Roberto, Mitrov, Lazar, Muenchhoff, Maximilian, Nauck, Matthias, Pley, Christina, Reese, Jens-Peter, Rieg, Siegbert, and Scherer, Margarete
- Subjects
SARS-CoV-2 ,COVID-19 pandemic ,SARS Epidemic, 2002-2003 ,COVID-19 - Abstract
With the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), global researchers were confronted with major challenges. The German National Pandemic Cohort Network (NAPKON) was launched in fall 2020 to effectively leverage resources and bundle research activities in the fight against the coronavirus disease 2019 (COVID-19) pandemic. We analyzed the setup phase of NAPKON as an example for multicenter studies in Germany, highlighting challenges and optimization potential in connecting 59 university and nonuniversity study sites. We examined the ethics application process of 121 ethics submissions considering durations, annotations, and outcomes. Study site activation and recruitment processes were investigated and related to the incidence of SARS-CoV-2 infections. For all initial ethics applications, the median time to a positive ethics vote was less than two weeks and 30 of these study sites (65%) joined NAPKON within less than three weeks each. Electronic instead of postal ethics submission (9.5 days (Q1: 5.75, Q3: 17) vs. 14 days (Q1: 11, Q3: 26), p value = 0.01) and adoption of the primary ethics vote significantly accelerated the ethics application process. Each study center enrolled a median of 37 patients during the 14-month observation period, with large differences depending on the health sector. We found a positive correlation between recruitment performance and COVID-19 incidence as well as hospitalization incidence. Our analysis highlighted the challenges and opportunities of the federated system in Germany. Digital ethics application tools, adoption of a primary ethics vote and standardized formal requirements lead to harmonized and thus faster study initiation processes during a pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Impact of Clinical Study Implementation on Data Quality Assessments - Using Contradictions within Interdependent Health Data Items as a Pilot Indicator.
- Author
-
YUSUF, Khalid O., CHAPLINSKAYA-SOBOL, Irina, SCHONEBERG, Anne, HANSS, Sabine, VALENTIN, Heike, LORENZ-DEPIEREUX, Bettina, HANSCH, Stefan, FIEDLER, Karin, SCHERER, Margarete, SIKDAR, Shimita, MILJUKOV, Olga, REESE, Jens-Peter, WAGNER, Patricia, BRÖHL, Isabel, GEISLER, Ramsia, VEHRESCHILD, Jörg J., BLASCHKE, Sabine, BELLINGHAUSEN, Carla, MILOVANOVIC, Milena, and KREFTING, Dagmar
- Abstract
Introduction: Contradiction is a relevant data quality indicator to evaluate the plausibility of interdependent health data items. However, while contradiction assessment is achieved using domain-established contradictory dependencies, recent studies have shown the necessity for additional requirements to reach conclusive contradiction findings. For example, the oral or rectal methods used in measuring the body temperature will influence the thresholds of fever definition. The availability of this required information as explicit data items must be guaranteed during study design. In this work, we investigate the impact of activities related to study database implementation on contradiction assessment from two perspectives including: 1) additionally required metadata and 2) implementation of checks within electronic case report forms to prevent contradictory data entries. Methods: Relevant information (timestamps, measurement methods, units, and interdependency rules) required for contradiction checks are identified. Scores are assigned to these parameters and two different studies are evaluated based on the fulfillment of the requirements by two selected interdependent data item sets. Results: None of the studies have fulfilled all requirements. While timestamps and measurement units are found, missing information about measurement methods may impede conclusive contradiction assessment. Implemented checks are only found if data are directly entered. Discussion: Conclusive contradiction assessment typically requires metadata in the context of captured data items. Consideration during study design and implementation of data capture systems may support better data quality in studies and could be further adopted in primary health information systems to enhance clinical anamnestic documentation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Das Gesundheitsdatennutzungsgesetz – Potenzial für eine bessere Forschung und Gesundheitsversorgung.
- Author
-
Schmitt, Jochen, Bierbaum, Thomas, Geraedts, Max, Gothe, Holger, Härter, Martin, Hoffmann, Falk, Ihle, Peter, Kramer, Ursula, Klinkhammer-Schalke, Monika, Kuske, Silke, March, Stefanie, Reese, Jens-Peter, Schoffer, Olaf, Swart, Enno, Vollmar, Horst Christian, Walther, Felix, and Hoffmann, Wolfgang
- Published
- 2023
- Full Text
- View/download PDF
8. POTENZIALE DES GESUNDHEITSDATEN- NUTZUNGSGESETZES.
- Author
-
Schmitt, Jochen, Bierbaum, Thomas, Geraedts, Max, Gothe, Holger, Härter, Martin, Hoffmann, Falk, Ihle, Peter, Kramer, Ursula, Klinkhammer-Schalke, Monika, Kuske, Silke, March, Stefanie, Reese, Jens-Peter, Schoffer, Olaf, Swart, Enno, Vollmar, Horst Christian, Walther, Felix, and Hoffmann, Wolfgang
- Published
- 2023
9. Statistical biases due to anonymization evaluated in an open clinical dataset from COVID-19 patients.
- Author
-
Koll, Carolin E. M., Hopff, Sina M., Meurers, Thierry, Lee, Chin Huang, Kohls, Mirjam, Stellbrink, Christoph, Thibeault, Charlotte, Reinke, Lennart, Steinbrecher, Sarah, Schreiber, Stefan, Mitrov, Lazar, Frank, Sandra, Miljukov, Olga, Erber, Johanna, Hellmuth, Johannes C., Reese, Jens-Peter, Steinbeis, Fridolin, Bahmer, Thomas, Hagen, Marina, and Meybohm, Patrick
- Subjects
COVID-19 ,REGRESSION analysis ,DESCRIPTIVE statistics ,STATISTICS ,MATHEMATICAL models ,STATISTICAL bias - Abstract
Anonymization has the potential to foster the sharing of medical data. State-of-the-art methods use mathematical models to modify data to reduce privacy risks. However, the degree of protection must be balanced against the impact on statistical properties. We studied an extreme case of this trade-off: the statistical validity of an open medical dataset based on the German National Pandemic Cohort Network (NAPKON), which was prepared for publication using a strong anonymization procedure. Descriptive statistics and results of regression analyses were compared before and after anonymization of multiple variants of the original dataset. Despite significant differences in value distributions, the statistical bias was found to be small in all cases. In the regression analyses, the median absolute deviations of the estimated adjusted odds ratios for different sample sizes ranged from 0.01 [minimum = 0, maximum = 0.58] to 0.52 [minimum = 0.25, maximum = 0.91]. Disproportionate impact on the statistical properties of data is a common argument against the use of anonymization. Our analysis demonstrates that anonymization can actually preserve validity of statistical results in relatively low-dimensional data. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics.
- Author
-
Schons, Maximilian, Pilgram, Lisa, Reese, Jens-Peter, Stecher, Melanie, Anton, Gabriele, Appel, Katharina S., Bahmer, Thomas, Bartschke, Alexander, Bellinghausen, Carla, Bernemann, Inga, Brechtel, Markus, Brinkmann, Folke, Brünn, Clara, Dhillon, Christine, Fiessler, Cornelia, Geisler, Ramsia, Hamelmann, Eckard, Hansch, Stefan, Hanses, Frank, and Hanß, Sabine
- Subjects
SARS-CoV-2 ,COVID-19 ,ACADEMIC medical centers - Abstract
The German government initiated the Network University Medicine (NUM) in early 2020 to improve national research activities on the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic. To this end, 36 German Academic Medical Centers started to collaborate on 13 projects, with the largest being the National Pandemic Cohort Network (NAPKON). The NAPKON's goal is creating the most comprehensive Coronavirus Disease 2019 (COVID-19) cohort in Germany. Within NAPKON, adult and pediatric patients are observed in three complementary cohort platforms (Cross-Sectoral, High-Resolution and Population-Based) from the initial infection until up to three years of follow-up. Study procedures comprise comprehensive clinical and imaging diagnostics, quality-of-life assessment, patient-reported outcomes and biosampling. The three cohort platforms build on four infrastructure core units (Interaction, Biosampling, Epidemiology, and Integration) and collaborations with NUM projects. Key components of the data capture, regulatory, and data privacy are based on the German Centre for Cardiovascular Research. By April 01, 2022, 34 university and 40 non-university hospitals have enrolled 5298 patients with local data quality reviews performed on 4727 (89%). 47% were female, the median age was 52 (IQR 36–62-) and 50 pediatric cases were included. 44% of patients were hospitalized, 15% admitted to an intensive care unit, and 12% of patients deceased while enrolled. 8845 visits with biosampling in 4349 patients were conducted by April 03, 2022. In this overview article, we summarize NAPKON's design, relevant milestones including first study population characteristics, and outline the potential of NAPKON for German and international research activities. Trial registrationhttps://clinicaltrials.gov/ct2/show/NCT04768998.https://clinicaltrials.gov/ct2/show/NCT04747366.https://clinicaltrials.gov/ct2/show/NCT04679584 [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Trends in resource utilization and cost of illness in patients with active epilepsy in Germany from 2003 to 2020.
- Author
-
Willems, Laurent M., Hochbaum, Maja, Zöllner, Johann Philipp, Schulz, Juliane, Menzler, Katja, Langenbruch, Lisa, Kovac, Stjepana, Knake, Susanne, von Podewils, Felix, Hamacher, Mario, Hamer, Hajo M., Reese, Jens‐Peter, Frey, Katharina, Rosenow, Felix, and Strzelczyk, Adam
- Subjects
ECONOMIC aspects of diseases ,UNEMPLOYMENT ,PEOPLE with epilepsy ,EARLY retirement ,PART-time employment ,MEDICAL care costs - Abstract
Objective: This study was undertaken to calculate epilepsy‐related direct, indirect, and total costs in adult patients with active epilepsy (ongoing unprovoked seizures) in Germany and to analyze cost components and dynamics compared to previous studies from 2003, 2008, and 2013. This analysis was part of the Epi2020 study. Methods: Direct and indirect costs related to epilepsy were calculated with a multicenter survey using an established and validated questionnaire with a bottom‐up design and human capital approach over a 3‐month period in late 2020. Epilepsy‐specific costs in the German health care sector from 2003, 2008, and 2013 were corrected for inflation to allow for a valid comparison. Results: Data on the disease‐specific costs for 253 patients in 2020 were analyzed. The mean total costs were calculated at €5551 (±€5805, median = €2611, range = €274–€21 667) per 3 months, comprising mean direct costs of €1861 (±€1905, median = €1276, range = €327–€13 158) and mean indirect costs of €3690 (±€5298, median = €0, range = €0–€11 925). The main direct cost components were hospitalization (42.4%), antiseizure medication (42.2%), and outpatient care (6.2%). Productivity losses due to early retirement (53.6%), part‐time work or unemployment (30.8%), and seizure‐related off‐days (15.6%) were the main reasons for indirect costs. However, compared to 2013, there was no significant increase of direct costs (−10.0%), and indirect costs significantly increased (p <.028, +35.1%), resulting in a significant increase in total epilepsy‐related costs (p <.047, +20.2%). Compared to the 2013 study population, a significant increase of cost of illness could be observed (p =.047). Significance: The present study shows that disease‐related costs in adult patients with active epilepsy increased from 2013 to 2020. As direct costs have remained constant, this increase is attributable to an increase in indirect costs. These findings highlight the impact of productivity loss caused by early retirement, unemployment, working time reduction, and seizure‐related days off. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Multicenter, cross‐sectional study of the costs of illness and cost‐driving factors in adult patients with epilepsy.
- Author
-
Willems, Laurent M., Hochbaum, Maja, Frey, Katharina, Schulz, Juliane, Menzler, Katja, Langenbruch, Lisa, Kovac, Stjepana, Immisch, Ilka, von Podewils, Felix, Hamacher, Mario, Siebenbrodt, Kai, Rosenow, Felix, Reese, Jens‐Peter, and Strzelczyk, Adam
- Subjects
ECONOMIC aspects of diseases ,PEOPLE with epilepsy ,ECONOMIC impact of disease ,LIVING alone ,MULTIPLE regression analysis - Abstract
Objective: This study was undertaken to quantify epilepsy‐related costs of illness (COI) in Germany and identify cost‐driving factors. Methods: COI were calculated among adults with epilepsy of different etiologies and severities. Multiple regression analysis was applied to determine any epilepsy‐related and sociodemographic factors that serve as cost‐driving factors. Results: In total, 486 patients were included, with a mean age of 40.5 ± 15.5 years (range = 18–83 years, 58.2% women). Mean 3‐month COI were estimated at €4911, €2782, and €2598 for focal, genetic generalized, and unclassified epilepsy, respectively. The mean COI for patients with drug‐refractory epilepsy (DRE; €7850) were higher than those for patients with non‐DRE (€4720), patients with occasional seizures (€3596), or patients with seizures in remission for >1 year (€2409). Identified cost‐driving factors for total COI included relevant disability (unstandardized regression coefficient b = €2218), poorer education (b = €2114), living alone (b = €2612), DRE (b = €1831), and frequent seizures (b = €2385). Younger age groups of 18–24 years (b = −€2945) and 25–34 years (b = −€1418) were found to have lower overall expenditures. A relevant disability (b = €441), DRE (b = €1253), frequent seizures (b = €735), and the need for specialized daycare (b = €749) were associated with higher direct COI, and poorer education (b = €1969), living alone (b = €2612), the presence of a relevant disability (b = €1809), DRE (b = €1831), and frequent seizures (b = €2385) were associated with higher indirect COI. Significance: This analysis provides up‐to‐date COI data for use in further health economics analyses, highlighting the high economic impacts associated with disease severity, disability, and disease‐related loss of productivity among adult patients with epilepsy. The identified cost drivers could be used as therapeutic and socioeconomic targets for future cost‐containment strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. The Structured Delegation of Medical Care Services for Patients With Inflammatory Rheumatic Diseases.
- Author
-
Krause, Dietmar, Mai, Anna, Denz, Robin, Johow, Johannes, Reese, Jens-Peter, Westerhoff, Benjamin, Klaaßen-Mielke, Renate, Timmesfeld, Nina, Rittstieg, Annette, Saracbasi-Zender, Ertan, Günzel, Judith, Klink, Claudia, Schmitz, Elmar, Fendler, Claas, Raub, Wolf, Böddeker, Stephanie, Dybowski, Friedrich, Hübner, Georg, Menne, Hans-Jürgen, and Lakomek, Heinz-Jürgen
- Subjects
MEDICAL care ,RHEUMATOID arthritis ,RHEUMATISM ,PHYSICIANS ,RHEUMATOLOGISTS ,QUALITY of life ,PSORIATIC arthritis ,PHYSICIAN supply & demand - Abstract
Background: In some areas of Germany, there is a shortage of specialist physicians for patients with inflammatory rheumatic diseases. Delegating certain medical care services to qualified, specialized rheumatological assistants (SRAs) might be an effective way to supplement the available capacity for specialized medical care. Methods: Patients under stable treatment for rheumatoid arthritis (RA) or psoriatic arthritis (PsA) were included in this trial, which was designed to demonstrate, in a first step, the non-inferiority of a form of care involving delegation of physicians' tasks to SRAs (team-based care), in comparison to standard care, with respect to changes in disease activity at one year. "Non-inferiority," in this context, means either superiority or else an irrelevant extent of inferiority. In a second step, in case non-inferiority could be shown, the superiority of team-based care with respect to changes in patients' health-related quality of life would be tested as well. Disease activity was measured with the Disease Activity Score 28, and health-related quality of life with the EQ-5D-5L. This was a randomized, multicenter, rater-blinded trial with two treatment arms (team-based care and standard care). The statistical analysis was performed with mixed linear models (DRKS00015526). Results: From September 2018 to June 2019, 601 patients from 14 rheumatological practices and 3 outpatient rheumatological clinics in the German states of North Rhine--Westphalia and Lower Saxony were randomized to either team-based or standard care. Team-based care was found to be non-inferior to standard care with respect to changes in disease activity (adjusted difference = -0.19; 95% confidence interval [-0.36; -0.02]; p <0.001 for non-inferiority). Superiority with respect to health-related quality of life was not demonstrated (adjusted difference = 0.02 [-0.02; 0.05], p = 0.285). Conclusion: Team-based care, with greater integration of SRAs, is just as good as standard care in important respects. Trained SRAs can effectively support rheumatologists in the care of stable patients with RA or PsA. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Brief imagery rescripting vs. usual care and treatment advice in refugees with posttraumatic stress disorder: study protocol for a multi-center randomized-controlled trial.
- Author
-
Steil, Regina, Lechner-Meichsner, Franziska, Johow, Johannes, Krüger-Gottschalk, Antje, Mewes, Ricarda, Reese, Jens-Peter, Schumm, Hannah, Weise, Cornelia, Morina, Nexhmedin, and Ehring, Thomas
- Subjects
POST-traumatic stress disorder ,VIRTUAL reality therapy ,THERAPEUTIC alliance ,QUALITY of life ,REFUGEES ,RESEARCH protocols ,EMIGRATION & immigration - Abstract
Copyright of European Journal of Psychotraumatology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2021
- Full Text
- View/download PDF
15. Versorgung von Parkinson-Patienten in Deutschland.
- Author
-
Stangl, Stephanie, Haas, Kirsten, Eggers, Carsten, Reese, Jens-Peter, Tönges, Lars, and Volkmann, Jens
- Abstract
Copyright of Der Nervenarzt is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
16. Nurse-led care versus physician-led care in the management of rheumatoid arthritis and psoriatic arthritis (StaerkeR): study protocol for a multi-center randomized controlled trial.
- Author
-
Mai, Anna, Braun, Jürgen, Reese, Jens-Peter, Westerhoff, Benjamin, Trampisch, Ulrike, Klaassen-Mielke, Renate, Timmesfeld, Nina, Trampisch, Hans J., and Krause, Dietmar
- Subjects
PSORIATIC arthritis ,RHEUMATOID arthritis ,RANDOMIZED controlled trials ,CLINICAL trial registries ,PATIENT satisfaction - Abstract
Background: In Germany, the care of patients with inflammatory arthritis could be improved. Although specialized rheumatology nurses could take over substantial aspects of patient care, this hardly occurs in Germany. Thus, the aim of the study is to examine structured nursing consultation in rheumatology practices.Methods/design: In total, 800 patients with a stable course of rheumatoid arthritis or psoriatic arthritis in 20 centers in North Rhine-Westphalia and Lower Saxony will be randomized to either nurse-led care or standard care. Participating nurses will study for a special qualification in rheumatology and trial-specific issues. It is hypothesized that nurse-led care is non-inferior to standard care provided by rheumatologists with regard to a reduction of disease activity (DAS28) while it is hypothesized to be superior regarding changes in health-related quality of life (EQ-5D-5L) after 1 year. Secondary outcomes include functional capacity, patient satisfaction with treatment, and resource consumption.Discussion: Since there is insufficient care of rheumatology patients in Germany, the study may be able to suggest improvements. Nurse-led care has the potential to provide more efficient and effective patient care. This includes a more stringent implementation of the treat-to-target concept, which may lead to a higher percentage of patients reaching their treatment targets, thereby improving patient-related outcomes, such as quality of life, functional capacity, and participation. Additionally, nurse-led care may be highly cost-effective. Finally, this project may form the basis for a sustainable implementation of nurse-led care in standard rheumatology care in Germany.Trial Registration: German Clinical Trials Register, DRKS00015526. Registered on 11 January 2019. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
17. Analyse verschiedener Qualitätsmanagementsysteme in Arztpraxen für Sachsen.
- Author
-
Gumpert, Marcus and Reese, Jens-Peter
- Published
- 2019
- Full Text
- View/download PDF
18. General Trends in Prices and Prescription Patterns of Anticonvulsants in Germany between 2000 and 2017: Analysis of National and Cohort-Based Data.
- Author
-
Willems, Laurent M., Hamer, Hajo M., Knake, Susanne, Rosenow, Felix, Reese, Jens-Peter, and Strzelczyk, Adam
- Published
- 2019
- Full Text
- View/download PDF
19. Prescription of Benzodiazepines and Related Drugs in Patients with Mild Cognitive Deficits and Alzheimer's Disease.
- Author
-
Hessmann, Philipp, Dodel, Richard, Baum, Erika, Müller, Matthias J., Paschke, Greta, Kis, Bernhard, Zeidler, Jan, Klora, Mike, Reese, Jens-Peter, and Balzer-Geldsetzer, Monika
- Subjects
BENZODIAZEPINES ,ALTERNATIVE medicine ,ALZHEIMER'S disease ,NEUROBEHAVIORAL disorders ,MILD cognitive impairment - Abstract
Introduction Benzodiazepines and related drugs (BZDR) should be avoided in patients with cognitive impairment. We evaluated the relationship between a BZDR treatment and the health status of patients with Alzheimer's disease (AD). Methods Cross-sectional study in 395 AD patients using bivariate and multiple logistic analyses to assess correlations between the prescription of BZDR and patients' characteristics (cognitive and functional capacity, health-related quality of life (HrQoL), neuropsychiatric symptoms). Results BZDR were used in 12.4% (n=49) of all participants. In bivariate analyses, the prescription was associated with a lower HrQoL, a higher need of care, and the presence of anxiety. Multivariate models revealed a higher risk of BZDR treatment in patients with depression (OR 3.85, 95% CI: 1.45 – 10.27). Community-dwelling participants and those treated by neurologists/psychiatrists had a lower risk of receiving BZDR (OR 0.33, 95% CI: 0.12 – 0.89 and OR 0.16, 95% CI: 0.07 – 0.36). Discussion The inappropriate use of BZDR conflicts with national and international guidelines. We suggest evaluating indications and treatment duration and improving the knowledge of alternative therapies in healthcare institutions. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany.
- Author
-
Mengel, David, Fraune, Linda, Sommer, Norbert, Stettner, Mark, Reese, Jens Peter, Dams, Judith, Glynn, Robert James, Balzer‐Geldsetzer, Monika, Dodel, Richard, Tackenberg, Björn, and Balzer-Geldsetzer, Monika
- Subjects
THERAPEUTIC use of immunoglobulins ,IMMUNOLOGICAL adjuvants ,COMPARATIVE studies ,DEMOGRAPHY ,ECONOMIC aspects of diseases ,RESEARCH methodology ,MEDICAL cooperation ,GUILLAIN-Barre syndrome ,PSYCHOLOGICAL tests ,QUALITY of life ,REGRESSION analysis ,RESEARCH ,EVALUATION research ,SEVERITY of illness index ,THERAPEUTICS - Abstract
Introduction: Cost of illness studies are essential to estimate societal costs of chronic inflammatory demyelinating polyneuropathy (CIDP) and identify cost-driving factors.Methods: In total, 108 patients were recruited from 3 specialized neuroimmunological clinics. Costs were calculated for a 3-month period, including direct and indirect costs. The following outcomes were assessed: inflammatory neuropathy cause and treatment disability scale, Mini-Mental State Examination, Beck Depression Inventory, Charlson comorbidity index, EuroQol-5D, World Health Organization quality of life instrument, and socioeconomic status. Univariate and multivariate analyses were applied to identify cost-driving factors.Results: Total quarterly costs were €11,333. Direct costs contributed to 83% of total costs (€9,423), whereas indirect costs accounted for 17% (€1,910) of total costs. The cost of intravenous immunoglobulin (IVIg) was the main determinant of total costs (67%). Reduced health-related quality of life and depressive symptoms were identified as independent predictors of higher total costs.Discussion: CIDP is associated with high societal costs, mainly resulting from the cost of IVIg treatment. Muscle Nerve 58: 681-687, 2018. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
21. Antipsychotic treatment of community-dwelling and institutionalised patients with dementia in Germany.
- Author
-
Hessmann, Philipp, Dodel, Richard, Baum, Erika, Müller, Matthias J., Paschke, Greta, Kia, Bernhard, Zeidler, Jan, Klora, Mike, Reese, Jens-Peter, and Balzer-Geldsetzer, Monika
- Subjects
ANTIPSYCHOTIC agents ,ALZHEIMER'S disease ,COGNITION ,CONFIDENCE intervals ,DEMENTIA ,DRUG utilization ,NURSING home residents ,PSYCHOTHERAPY patients ,QUALITY of life ,QUESTIONNAIRES ,STATISTICS ,LOGISTIC regression analysis ,ACTIVITIES of daily living ,MULTIPLE regression analysis ,PSYCHIATRIC treatment ,INDEPENDENT living ,CROSS-sectional method ,SEVERITY of illness index ,ODDS ratio - Abstract
Objective: A restrictive use of antipsychotic drugs in patients with Alzheimer's disease (AD) is recommended due to an increased risk of cerebrovascular events and mortality. We hypothesise that the prescription of antipsychotics is associated with the patients' socio-demographic and clinical status (e.g., dementia severity). Methods: The prescription of antipsychotics was cross-sectionally evaluated in 272 community-dwelling and 123 institutionalised patients with AD across all severity stages of dementia. The patients' clinical characteristics covered the cognitive status, neuropsychiatric symptoms, daily activities, and quality of life (HrQoL). To determine associations with the use of antipsychotics bivariate and logistic regression analyses were conducted. Results: Totally, 25% of the patients were treated with antipsychotics. significantly less frequently than nursing home inhabitants (15.1% vs. 45.5%). Severely demented patients (MMSE 0-9) received antipsychotics most often (51.5%). Additionally, multiple regression analyses revealed a higher chance of prescription for participants with depressive symptoms (OR 2.3, 95% CI: 1.019-5.160) and those treated by neuropsychiatric specialists (OR 3.4, 95% CI: 1.408-8.328). Conclusions: Further longitudinal studies are required to assess the appropriateness of indications for antipsychotics and the reasons for a higher use in nursing home inhabitants and patients with severe dementia and depression. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
22. Tramadol prescription patterns in patients followed by general practitioners and orthopedists in Germany in the year 2015.
- Author
-
Kostev, Karel, Von Vultée, Christian, Usinger, Diethard M., and Reese, Jens-Peter
- Subjects
PAIN management ,TRAMADOL ,ORTHOPEDISTS ,HEALTH insurance ,FOLLOW-up studies (Medicine) ,PUBLIC health ,THERAPEUTICS ,PAIN diagnosis ,THERAPEUTIC use of narcotics ,ANALGESICS ,COMBINATION drug therapy ,DRUG utilization ,FAMILY medicine ,MEDICAL prescriptions ,ORTHOPEDICS ,PAIN ,RETROSPECTIVE studies - Abstract
Objectives: The aim of this study was to analyze tramadol prescription patterns in acute pain patients followed by general practitioners and orthopedists in Germany.Methods: This study included patients ≥18 years diagnosed with acute pain who received at least one tramadol prescription each in one of 1,129 general or 179 orthopedic practices in Germany between January and December 2015 (index date). Patients were excluded if they had received a prescription for another analgesic in the year prior to the index date, had a follow-up of less than 15 months after the index date, or were prescribed tramadol for a period of more than three months. The main outcome of this retrospective study was the share of patients receiving tramadol in combination therapy. Combination therapy was defined as the prescription of tramadol in conjunction with at least one other analgesic during the same medical visit.Results: The present study included a total of 8,766 individuals. Overall, 1,492 (22.0%) of tramadol patients seen by general practitioners and 370 (18.7%) of those seen by orthopedists received tramadol in combination with other analgesics. Although this proportion was similar throughout the different subgroups in orthopedic practices, it was considerably higher in patients >80 years and in those with private health insurance coverage in general practices.Conclusions: Approximately one of five tramadol patients was prescribed tramadol in combination therapy. Further research is needed to gain a better understanding of the demographic and clinical factors that have an effect on tramadol prescription patterns in Germany. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
23. Prevalence, Duration and Severity of Parkinson’s Disease in Germany: A Combined Meta-Analysis from Literature Data and Outpatient Samples.
- Author
-
Enders, Dirk, Balzer-Geldsetzer, Monika, Riedel, Oliver, Dodel, Richard, Wittchen, Hans-Ulrich, Sensken, Sven-Christian, Wolff, Björn, and Reese, Jens-Peter
- Subjects
DISEASE prevalence ,PARKINSON'S disease patients ,MEDICAL care ,OUTPATIENT medical care ,DISEASE duration - Abstract
Background: Epidemiological data on the prevalence of Parkinson’s disease (PD) in Germany are limited. The aims of this study were to estimate the age- and gender-specific prevalence of PD in Germany as well as the severity and illness duration. Summary: A systematic literature search was performed in 5 different databases. European studies were included if they reported age- and gender-specific numbers of prevalence rates of PD. Meta-analytic approaches were applied to derive age- and gender-specific pooled prevalence estimates. Data of 4 German outpatient samples were incorporated to calculate the proportion of patients with PD in Germany grouped by Hoehn and Yahr (HY) stages and disease duration. In the German population, 178,169 cases of PD were estimated (prevalence: 217.22/100,000). The estimated relative illness duration was 40% with less than 5 years, 31% with 5–9 years, and 29% with more than 9 years. The proportions for different HY stages were estimated at 13% (I), 30% (II), 35% (III), 17% (IV), and 4% (V), respectively. Key Message: We provide an up-to-date estimation of age-and gender-specific as well as severity-based prevalence figures for PD in Germany. Further community studies are needed to estimate population-based severity distributions and distributions of non-motor symptoms in PD. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
24. Costs and cost-driving factors for acute treatment of adults with status epilepticus: A multicenter cohort study from Germany.
- Author
-
Kortland, Lena‐Marie, Alfter, Anne, Bähr, Oliver, Carl, Barbara, Dodel, Richard, Freiman, Thomas M., Hubert, Kristina, Jahnke, Kolja, Knake, Susanne, Podewils, Felix, Reese, Jens‐Peter, Runge, Uwe, Senft, Christian, Steinmetz, Helmuth, Rosenow, Felix, and Strzelczyk, Adam
- Subjects
STATUS epilepticus treatment ,DISEASES in adults ,MEDICAL care costs ,PUBLIC health ,HOSPITAL admission & discharge - Abstract
Objective To provide first data on inpatient costs and cost-driving factors due to nonrefractory status epilepticus ( NSE), refractory status epilepticus ( RSE), and super-refractory status epilepticus ( SRSE). Methods In 2013 and 2014, all adult patients treated due to status epilepticus ( SE) at the university hospitals in Frankfurt, Greifswald, and Marburg were analyzed for healthcare utilization. Results We evaluated 341 admissions in 316 patients (65.7 ± [standard deviation]18.2 years; 135 male) treated for SE. Mean costs of hospital treatment were €14,946 (median €5,278, range €776-€152,911, €787 per treatment day) per patient per admission, with a mean length of stay ( LOS) of 19.0 days (median 14.0, range 1-118). Course of SE had a significant impact on mean costs, with €8,314 in NSE (n = 137, median €4,597, €687 per treatment day, 22.3% of total inpatient costs due to SE), €13,399 in RSE (n = 171, median €7,203, €638/day, 45.0% of total costs, p < 0.001), and €50,488 in SRSE (n = 33, median €46,223, €1,365/day, 32.7% of total costs, p < 0.001). Independent cost-driving factors were SRSE, ventilation, and LOS of >14 days. Overall mortality at discharge was 14.4% and significantly higher in RSE/ SRSE (20.1%) than in NSE (5.8%). Significance Acute treatment of SE, and particularly SRSE and ventilation, are associated with high hospital costs and prolonged LOS. Extrapolation to the whole of Germany indicates that SE causes hospital costs of >€200 million per year. Along with the demographic change, incidence of SE will increase and costs for hospital treatment and sequelae of SE will rise. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
25. Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications.
- Author
-
Dams, Judith, Balzer‐Geldsetzer, Monika, Siebert, Uwe, Deuschl, Günther, Schuepbach, W.M. Michael, Krack, Paul, Timmermann, Lars, Schnitzler, Alfons, Reese, Jens‐Peter, Dodel, Richard, Schuepbach, W.M.M., Rau, J., Knudsen, K., Volkmann, J., Krack, P., Timmermann, L., Hälbig, T.D., Hesekamp, H., Navarro, S.M., and Meier, N.
- Subjects
PARKINSON'S disease treatment ,ANTIPARKINSONIAN agents ,COST effectiveness ,DIENCEPHALON ,HEALTH outcome assessment ,PARKINSON'S disease ,QUALITY of life ,QUESTIONNAIRES ,DEEP brain stimulation ,DISEASE complications ,ECONOMICS ,THERAPEUTICS - Abstract
Background: Recent research efforts have focused on the effects of deep brain stimulation of the subthalamic nucleus (STN DBS) for selected patients with mild-to-moderate PD experiencing motor complications.Objectives: We assessed the cost utility of subthalamic DBS compared with the best medical treatment for German patients below the age of 61 with early motor complications of PD.Methods: We applied a previously published Markov model that integrated health utilities based on EuroQoL and direct costs over patients' lifetime adjusted to the German health care payer perspective (year of costing: 2013). Effectiveness was evaluated using the Parkinson's Disease Questionnaire 39 summary index. We performed sensitivity analyses to assess uncertainty.Results: In the base-case analysis, the incremental cost-utility ratio for STN DBS compared to best medical treatment was 22,700 Euros per quality-adjusted life year gained. The time to, and costs for, battery exchange had a major effect on the incremental cost-utility ratios, but never exceeded a threshold of 50,000 Euros per quality-adjusted life year.Conclusions: Our decision analysis supports the fact that STN DBS at earlier stages of the disease is cost-effective in patients below the age of 61 when compared with the best medical treatment in the German health care system. This finding was supported by detailed sensitivity analyses reporting robust results. Whereas the EARLYSTIM study has shown STN DBS to be superior to medical therapy with respect to quality of life for patients with early motor complications, this further analysis has shown its cost-effectiveness. © 2016 International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
26. Health-Related Quality of Life in Patients with Alzheimer's Disease in Different German Health Care Settings.
- Author
-
Heßmann, Philipp, Seeberg, Greta, Reese, Jens Peter, Dams, Judith, Baum, Erika, Müller, Matthias J., Dodel, Richard, and Balzer-Geldsetzer, Monika
- Subjects
QUALITY of life ,CARE of dementia patients ,CARE of Alzheimer's patients ,MENTAL depression ,DEMENTIA ,ALZHEIMER'S disease ,ALZHEIMER'S disease treatment ,THERAPEUTICS ,PSYCHOLOGY of caregivers ,COMPARATIVE studies ,NEUROPSYCHOLOGICAL tests ,RESEARCH methodology ,MEDICAL cooperation ,MULTIVARIATE analysis ,PSYCHOLOGICAL tests ,RESEARCH ,SELF-evaluation ,EVALUATION research ,RESIDENTIAL care ,SEVERITY of illness index ,GERIATRIC Depression Scale ,PSYCHOLOGY - Abstract
The purpose of this study is to evaluate the health-related quality of life (HrQoL) of patients with Alzheimer's disease (AD) in different care settings (institutionalized versus community-dwelling) across all severity stages of dementia. Patients were consecutively recruited with their primary caregivers (123 inpatients and 272 outpatients), and the impact of patient-related parameters such as behavioral and psychological symptoms of dementia (BPSD) (Geriatric Depression Scale [GDS] and Neuropsychiatric Inventory [NPI]) and functional capacity (Alzheimer's Disease Cooperative Study-Activities of Daily Living [ADCS-ADL]) on HrQoL was analyzed. Patients' HrQoL was assessed using self-reported and caregiver-rated generic (EuroQoL Instrument) and dementia-specific (Quality of Life-Alzheimer's Disease [Qol-AD]) scales. Patients reported a considerably higher HrQoL than their caregivers on the QoL-AD, EQ-5D, and EQ VAS (p < 0.001). Different dementia severity groups showed significantly worse results in HrQoL for patients with lower MMSE scores. The mean self-reported QoL-AD decreased from 32.3±5.7 in the group with the highest MMSE scores to 27.1±5.5 in patients with the lowest MMSE scores (p < 0.001). A considerably lower HrQoL was shown for institutionalized patients versus participants in outpatient settings (proxy-rated QoL-AD 19.7±4.6 versus 26.0±7.1, p < 0.001). Depressive symptoms (GDS), BPSD (NPI), and reduced functional capacity (ADCS-ADL) were evaluated for their impact on patients' HrQoL. Multivariate models explained between 22% and 54% of the variance in patients' HrQoL. To analyze the causative direction of the reported associations, further longitudinal studies should be conducted. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
27. Versorgung von Schlafapnoe-Patienten in Hessen.
- Author
-
Mayer, Geert, Apelt, Sandra, Hessmann, Philipp, Reese, Jens-Peter, Dodel, Richard, and Heitmann, Jörg
- Abstract
Copyright of Somnologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2015
- Full Text
- View/download PDF
28. Prescription of Memantine/Donepezil: Influence of Industry Payments?
- Author
-
Reese, Jens-Peter
- Published
- 2021
- Full Text
- View/download PDF
29. Geschmacksstörungen bei long COVID.
- Author
-
Behrend, Naomi, Winkelmann, Sanja, Korth, Alia, Voss, Bettina, Abou, Nasr Maher, Pudszuhn, Annett, Hofmann, VeitMaria, Schendzielorz, Philipp, Witzenrath, Martin, Krist, Lilian, Fricke, Julia, Bahmer, Thomas, Schreiber, Stefan, Keil, Thomas, Lieb, Wolfgang, Reese, Jens-Peter, Heuschmann, Peter, Hummel, Thomas, Borzikowsky, Christoph, and Laudien, Martin
- Published
- 2022
- Full Text
- View/download PDF
30. Geruchsstörungen bei Long-COVID.
- Author
-
Winkelmann, Sanja, Korth, Alia, Voss, Bettina, Abou, Nasr Maher, Behrend, Naomi, Pudszuhn, Annett, Hofmann, Veit Maria, Schendzielorz, Philipp, Witzenrath, Martin, Krist, Lilian, Fricke, Julia, Bahmer, Thomas, Schreiber, Stefan, Keil, Thomas, Lieb, Wolfgang, Reese, Jens-Peter, Heuschmann, Peter, Hummel, Thomas, Borzikowsky, Christoph, and Laudien, Martin
- Published
- 2022
- Full Text
- View/download PDF
31. Gustatory dysfunction in long COVID.
- Author
-
Behrend, Naomi, Winkelmann, Sanja, Korth, Alia, Voss, Bettina, Abou, Nasr Maher, Pudszuhn, Annett, Hofmann, Veit Maria, Schendzielorz, Philipp, Witzenrath, Martin, Krist, Lilian, Fricke, Julia, Bahmer, Thomas, Schreiber, Stefan, Keil, Thomas, Lieb, Wolfgang, Reese, Jens-Peter, Heuschmann, Peter, Hummel, Thomas, Borzikowsky, Christoph, and Laudien, Martin
- Published
- 2022
- Full Text
- View/download PDF
32. Olfactory dysfunction in Long-COVID.
- Author
-
Winkelmann, Sanja, Korth, Alia, Voss, Bettina, Abou Nasr, Maher, Behrend, Naomi, Pudszuhn, Annett, Hofmann, VeitMaria, Schendzielorz, Philipp, Witzenrath, Martin, Krist, Lilian, Fricke, Julia, Bahmer, Thomas, Schreiber, Stefan, Keil, Thomas, Lieb, Wolfgang, Reese, Jens-Peter, Heuschmann, Peter, Hummel, Thomas, Borzikowsky, Christoph, and Laudien, Martin
- Published
- 2022
- Full Text
- View/download PDF
33. Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease.
- Author
-
Dodel, Richard, Jönsson, Bengt, Reese, Jens Peter, Winter, Yaroslav, Martinez‐Martin, Pablo, Holloway, Robert, Sampaio, Cristina, Růžička, Evžen, Hawthorne, Graeme, Oertel, Wolfgang, Poewe, Werner, Stebbins, Glenn, Rascol, Oliver, Goetz, Christopher G., and Schrag, Anette
- Abstract
ABSTRACT Health economic studies in Parkinson's disease (PD) have become increasingly common in recent years. Because several methodologies and instruments have been used to assess cost and outcomes in PD, the Movement Disorder Society (MDS) commissioned a Task Force to assess their properties and make recommendations regarding their use. A systematic literature review was conducted to explore the use of those instruments in PD and to determine which should be selected for this review. We assessed approaches to evaluate cost of illness (COI), cost effectiveness, and cost utilities, which include the use of direct (standard gamble, time trade-off. and visual analogue scales) and indirect instruments to measure health status and utilities. No validated instruments/models were identified for the evaluation of COI or cost-effectiveness in patients with PD; therefore, no instruments in this group are recommended. Among utility instruments, only a few of these outcome instruments have been used in the PD population, and only limited psychometric data are available for these instruments with respect to PD. Because psychometric data for further utility instruments in conditions other than PD already exist, the standard gamble and time trade-off methods and the EQ-5D (a European quality-of-life health states instrument) and Health Utility Index instruments met the criteria for scales that are 'recommended (with limitations),' but only the EQ-5D has been assessed in detail in PD patients. The MDS Task Force recommends further study of these instruments in the PD population to establish core psychometric properties. For the assessment of COI, the Task Force considers the development of a COI instrument specifically for PD, like that available for Alzheimer's disease. © 2013 Movement Disorder Society [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
34. CNI-1493 Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in the Acute MPTP Mouse Model of Parkinson's Disease.
- Author
-
Noelker, Carmen, Stuckenholz, Vanessa, Reese, Jens-Peter, alvarez-Fischer, Daniel, Sankowski, Roman, Rausch, Tanja, Oertel, Wolfgang H., Hartmann, andreas, van Patten, Sonya, al-abed, Yousef, and Bacher, Michael
- Subjects
NEUROLOGICAL disorders ,PARKINSON'S disease ,ANIMAL models in research ,NEURODEGENERATION ,DOPAMINERGIC neurons ,NEUROPHARMACOLOGY - Abstract
Background: Parkinson's disease (PD) is associated with neurodegeneration of dopaminergic neurons in the substantia nigra. Neuroinflammatory processes have been shown to be a key component of this neurodegeneration and, as such, small molecule compounds which inhibit these inflammatory events are a critical research focus. Objective: CNI-1493 is an anti-inflammatory compound that strongly inhibits macrophages and also stimulates the cholinergic anti-inflammatory pathway. We have examined whether CNI-1493 has a neuroprotective effect in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. Methods: CNI-1493 (8 mg/kg i.p.) or placebo administration was started 1 day before MPTP intoxication and repeated daily until sacrifice after MPTP intoxication. C57/Bl6 mice - either treated with CNI-1493 or with placebo - were injected intraperitoneally 4 times at 2-hour intervals with either 20 mg/kg MPTP-HCl or a corresponding volume of saline. Two or 7 days after the end of the MPTP intoxication, the animals were killed and their brains were processed for further analysis. Results: Administration of CNI-1493 markedly protected tyrosine hydroxylase-positive substantia nigra neurons against MPTP neurotoxicity. CNI-1493 treatment in the MPTP model was also accompanied by a profound reduction of activated microglia within the substantia nigra, as measured by ionized calcium-binding adapter molecule-1 staining. Conclusions: These findings support that CNI-1493 could reduce the MPTP-induced toxicity likely by inhibition of neuroinflammatory responses. The neuroprotective effect of CNI-1493 suggests that CNI-1493 might be a valuable neuroprotective candidate in the future treatment of PD. Copyright © 2012 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
35. Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease.
- Author
-
Dams, Judith, Siebert, Uwe, Bornschein, Bernhard, Volkmann, Jens, Deuschl, Günther, Oertel, Wolfgang H., Dodel, Richard, and Reese, Jens‐Peter
- Abstract
ABSTRACT In addition to medical treatment, deep brain stimulation has become an alternative therapeutic option in advanced Parkinson's disease. High initial costs of surgery have to be weighted against long-term gains in health-related quality of life. The objective of this study was to assess the cost-effectiveness of deep brain stimulation compared with long-term medical treatment. We performed a cost-utility analysis using a lifetime Markov model for Parkinson's disease. Health utilities were evaluated using the EQ-5D generic health status measure. Data on effectiveness and adverse events were obtained from clinical studies, published reports, or meta-analyses. Costs were assessed from the German health care provider perspective. Both were discounted at 3% per year. Key assumptions affecting costs and health status were investigated using one-way and two-way sensitivity analyses. The lifetime incremental cost-utility ratio for deep brain stimulation was €6700 per quality-adjusted life year (QALY) and €9800 and €2500 per United Parkinson's Disease Rating Scale part II (motor experiences of daily living) and part III (motor examination) score point gained, respectively. Deep brain stimulation costs were mainly driven by the cost of surgery and of battery exchange. Health status was improved and motor complications were reduced by DBS. Sensitivity analysis revealed that battery life time was the most influential parameter, with the incremental cost-utility ratio ranging from €20,000 per QALY to deep brain stimulation dominating medical treatment. Deep brain stimulation can be considered cost-effective, offering a value-for-money profile comparable to other well accepted health care technologies. Our data support adopting and reimbursing deep brain stimulation within the German health care system. © 2013 Movement Disorder Society [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
36. Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany-a nationwide population-based study in children and adults.
- Author
-
Hamer, Hajo, Dodel, Richard, Strzelczyk, Adam, Balzer-Geldsetzer, Monika, Reese, Jens-Peter, Schöffski, Oliver, Graf, Wolfgang, Schwab, Stefan, Knake, Susanne, Oertel, Wolfgang, Rosenow, Felix, and Kostev, Karel
- Subjects
DRUG utilization ,TREATMENT of epilepsy ,DRUG prices ,ANTICONVULSANTS ,CHILDHOOD epilepsy ,ADULTS - Abstract
Nationwide analyses of drug use can provide a prevalence estimate of the underlying disease and can help in understanding the characteristics of treatment. This study aimed for such analyses regarding the utilization of antiepileptic drugs (AED) for epilepsy in Germany. In 2009, all 4,115,705 AED prescriptions of all German patients with statutory health insurance (70,011,508 persons) were retrospectively analyzed. The IMS LRx database served as data source, which accesses nationwide pharmacy data centers processing all German prescription data. To establish the age and sex-specific percentage of patients taking AED because of epilepsy, we used a second database, Disease Analyzer, which covered a representative sample of the German population (7.2 million patients) and contained ICD10 codes alongside with prescription data. The period prevalence of patients taking AED because of epilepsy was 9.1/1,000 (children/adolescents: 5.2/1,000; elderly: 12.5/1,000). Of the patients, 83.1 % took at least one of four AED: valproate (29.8 %), carbamazepine (26.4 %), lamotrigine (21.4 %), and levetiracetam (16.9 %). Oxcarbazepine and sultiame were popular with pediatricians. Elderly patients frequently received phenytoin and primidone. More than half of the patients were treated by family physicians; 68 % took AED in monotherapy and 7.9 % received >2 AED (children/adolescents: 12.5 %). The costs for AED prescribed for epilepsy amounted to €285.1 Mio (median AED costs/patient: €158/a). The German 2009 prevalence of epileptic patients taking AED was 9.1/1,000. Family physicians cared for the majority of patients. Prevalence and prescribing patterns changed with age. Costs of AED against epilepsy added up to 1 % of total medication costs in Germany. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
37. Modelling the Cost Effectiveness of Treatments for Parkinson's Disease: A Methodological Review.
- Author
-
Dams, Judith, Bornschein, Bernhard, Reese, Jens Peter, Conrads-Frank, Annette, Oertel, Wolfgang H., Siebert, Uwe, and Dodel, Richard
- Subjects
PARKINSON'S disease treatment ,COST effectiveness ,MARKOV processes ,SINGLE-photon emission computed tomography - Abstract
The objective of this review was to assess models of cost effectiveness for Parkinson's disease (PD) published after July 2002 and to derive recommendations for future modelling. A systematic literature search was performed in the databases PubMed, Current Contents, EMBASE, EconLit, the Cochrane Database of Systematic Reviews, and DARE (Database of Abstracts of Reviews of Effectiveness), NHS EED (Economic Evaluation Database) and HTA (Health Technology Assessment) of the UK NHS Centre for Review and Dissemination (July 2002 to March 2010). Only fully published studies using decision trees, Markov models, individual simulation models or sets of mathematical equations were included. Most of the 11 studies identified used Markov models (n = 9) and two employed were based on decision trees. Based on the Hoehn & Yahr (HY) scale, authors evaluated the cost effectiveness of drug treatments (n = 6), surgical approaches such as deep brain stimulation (n = 1) or striatal cell grafting (n = 1), and diagnostic procedures such as single photon emission computed tomography (SPECT) testing (n = 3) over a time horizon of 1 year to lifetime. Costs were adapted to address a societal and/or healthcare provider/ third-party payer perspective. All but one of the interventions investigated were considered cost effective or cost saving. Cost-effectiveness modelling in PD between 2003 and 2010 showed only minor improvement when compared with our earlier review of models published from 1998 up to 2003. Cost-effectiveness modelling recommendations were complied with to only a limited extent, leaving room for quality improvement. More advanced modelling approaches may, so far, be underrepresented, but may be used in the future, driven by the research question. Adverse events of treatment, co-morbidities or disease complications are not yet sufficiently included in the models to adequately represent clinical reality. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
38. Economic Burden in a German Cohort of Patients with Multiple Sclerosis.
- Author
-
Reese, Jens Peter, John, Axel, Wienemann, Gabriele, Wellek, Anne, Sommer, Norbert, Tackenberg, Björn, Balzer-Geldsetzer, Monika, and Dodel, Richard
- Subjects
MULTIPLE sclerosis ,OUTPATIENT medical care ,MYELIN sheath diseases ,COHORT analysis - Abstract
Aims: To estimate costs of multiple sclerosis (MS) in a German cohort according to severity of the disease and clinical symptoms. Methods: 144 patients were recruited from an MS outpatient clinic. Costs were calculated according to current German health-economic guidelines from the perspective of the social health insurance system. Patients were either interviewed or completed a questionnaire. Cost assessment covered a 3-month period. Health outcomes were: Expanded Disability Status Scale, MS Functional Composite, Functional Assessment of MS, fatigue, depression (Beck Depression Inventory II) and patients' socioeconomic status. Multivariate linear regression identified independent cost predictors. Results: Total quarterly costs per patient were EUR 10,329 (95% CI 9,357-11,390). Direct costs were EUR 5,344 for the social health insurance system and EUR 140 for the patient. Drugs represented the major share of direct costs (and 35% of total costs); indirect costs accounted for 47% of total costs. Univariate and multivariate analyses identified age, disability, fatigue and depression as independent predictors for total, indirect or drug costs. Conclusion: MS represents a high economic burden, with direct costs exceeding indirect costs. To reduce costs, research should focus on prevention that slows down progression of MS. Rehabilitation and symptomatic treatment may have merits in decreasing indirect costs. Copyright © 2011 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
39. Cost and Care of Patients with Alzheimer's Disease: Clinical Predictors in German Health Care Settings.
- Author
-
Reese, Jens Peter, Heßmann, Philipp, Seeberg, Greta, Henkel, Dajana, Hirzmann, Pamela, Rieke, Jürgen, Baum, Erika, Dannhoff, Frank, Müller, Matthias J., Jessen, Frank, Geldsetzer, Monika-Balzer, and Dodel, Richard
- Subjects
ALZHEIMER'S patients ,DEMENTIA ,DISEASES in older people ,MEDICAL care costs ,NEURODEGENERATION - Abstract
The study aims to report service use and costs for patients with Alzheimer's disease (AD) and to explore the incremental influence of sociodemographic and illness-related determinants in ambulatory and inpatient settings within the German health care system. 395 patients with dementia were recruited at the following sites: 1) University hospital, 2) general practitioners' offices, 3) office-based neurologists, 4) a regional psychiatric hospital, and 5) nursing homes. Sociodemographic, economic, and clinical parameters were assessed using a standardized questionnaire. Informal care was not evaluated. Disease severity was measured using the Mini-Mental Status Examination and the Alzheimer's Disease Assessment Scale - Cognitive Subscale. Neuropsychiatric status was assessed using the Geriatric Depression Scale, the Neuropsychiatric Inventory, and the Alzheimer's Disease Cooperative-Study-Activities of Daily Living. Annual total costs were estimated to be $\euro$13,080 per patient. The most important cost component was (long-term) care, constituting about 43% of total costs. Indirect costs comprised about 18% of total costs and were mainly due to reductions in working time of caregivers. Poorer functional status was associated with higher total and caregiving costs. In multivariate analyses, we identified younger age, female gender, and impaired activities of daily living as independent predictors of higher costs. Given that care for patients with AD is complex and expensive, our models were only able to explain about 17-43% of the variability in total costs. This suggests that further social and individual factors considerably influence the costs associated with AD. Direct medical care costs and long-term care costs related differently to the patient's clinical characteristics. Longitudinal and population-based studies are necessary for thoroughly evaluating the burden of disease. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
40. Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy.
- Author
-
Winter, Yaroslav, Schepelmann, Karsten, Spottke, Annika, Claus, Detlef, Grothe, Christoph, Schröder, Rolf, Heuss, Dieter, Vielhaber, Stefan, Tackenberg, Björn, Mylius, Veit, Reese, Jens-Peter, Kiefer, Reinhard, Schrank, Bertold, Oertel, Wolfgang, and Dodel, Richard
- Subjects
AMYOTROPHIC lateral sclerosis ,MYASTHENIA gravis ,FACIOSCAPULOHUMERAL muscular dystrophy ,QUALITY of life ,NEUROMUSCULAR diseases ,MEDICAL care ,CLINICAL medicine - Abstract
Neuromuscular disorders are rare diseases with a chronic and debilitating course. Unfortunately, data on the health-related quality of life (HRQoL) in neuromuscular diseases are limited. The objective of this multicentre cross-sectional study was to compare the HRQoL in patients with amyotrophic lateral sclerosis (ALS), facioscapulohumeral muscular dystrophy (FSHD) and myasthenia gravis (MG) and to identify the determinants of the HRQoL in these diseases. We recruited 91 consecutive outpatients with ALS ( n = 37), FSHD ( n = 17) or MG ( n = 37) in seven specialized German health centres. The HRQoL was determined using the 36-Item Short Form Health Survey (SF-36) and the EuroQol (EQ-5D). Independent predictors of the HRQoL were identified using multiple regression analysis. The HRQoL in all domains of the SF-36, except for bodily pain, was significantly reduced. The domains related to physical health (physical functioning, physical role) were most affected. The EQ-5D-index score was most reduced in ALS (0.54) and least reduced in MG (0.89). Independent predictors of a reduced HRQoL were disease severity and depression in ALS, and disease severity, depression, older age and increased body-mass index in MG. The patterns of HRQoL-impairment in neuromuscular disorders share some common features, such as a more pronounced reduction in the HRQoL related to physical health, but there are a number of disease-specific features that should be considered in outcomes of clinical trials and treatment guidelines. In addition to the treatment of motor symptoms, greater attention should be paid to the treatment of depression, which was found to be among the independent predictors of the HRQoL in ALS and MG. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
41. Cost of illness in patients with Gilles de la Tourette’s syndrome.
- Author
-
Dodel, Ines, Reese, Jens Peter, Müller, Norbert, Münchau, Alexander, Balzer-Geldsetzer, Monika, Wasem, Jürgen, Oertel, Wolfgang H., Dodel, Richard, and Müller-Vahl, Kirsten
- Subjects
TOURETTE syndrome ,MEDICAL care costs ,PATIENTS ,MULTIVARIATE analysis ,HOSPITAL care - Abstract
We evaluated the health economic burden of patients with Gilles de la Tourette’s syndrome (GTS) in Germany over a 3-month observation period. Direct and indirect costs were evaluated in 200 outpatients with GTS (mean age 35 ± 11.5 years) in Germany. Patients were recruited from three outpatient departments that specialized in GTS and completed a semi-structured and self-rating interview with questionnaires screening for direct and indirect medical and non-medical costs, health status, depression, amount and severity of symptoms. Costs were obtained from various German medical economic resources. Indirect costs for lost productivity were calculated using the human capital approach. Costs were calculated from the point of view of healthcare and transfer payment providers and the individual patient. Multivariate regression analyses were performed to identify independent cost predictors. Costs are in year 2006–2007 values. Direct costs were 620 ± 1,697.1€, including rehabilitation 98.8 ± 993.6€, hospitalization 195.8 ± 1,267.8€, outpatient treatment 14.0 ± 40.6€, ancillary treatment 51.9 ± 137.4€. Drug costs were 223.1 ± 430.4. The indirect medical costs amounted to 2,511.3 ± 3,809.5€ for productivity loss and to 220.0 ± 1,092€ for absenteeism. The following variables were found to impact on direct costs: employment status, occupational advancement, depression, quality of life, age. Disease severity had no influence on cost. Because of the earlier age of disease onset, indirect costs are higher than direct costs. Interestingly, disease severity did not influence the resource need in this population. Unfortunately, no cost of illness studies are available for comparison. Further health economic studies, especially cost-effectiveness studies, are necessary for a basis for rational resource allocation. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
42. Health Economic Burden of Patients with Restless Legs Syndrome in a German Ambulatory Setting.
- Author
-
Dodel, Richard, Happe, Svenja, Peglau, Ines, Mayer, Geert, Wasem, Jürgen, Reese, Jens-Peter, Giani, Guido, Geraedts, Max, Trenkwalder, Claudia, Oertel, Wolfgang H., and Stiasny-Kolster, Karin
- Subjects
RESTLESS legs syndrome ,SLEEP disorders ,DISEASE prevalence ,PATIENTS ,OUTPATIENT medical care ,ECONOMIC aspects of diseases - Abstract
Background: The primary characteristics of restless legs syndrome (RLS), including severe sleep disorders, restlessness in the evening and discomfort while at rest, have substantial impact on normal daily activities. Because of the high prevalence of RLS in the general population, it is necessary to evaluate the economic impact of RLS. Objective: To determine the health economic burden of patients with RLS in Germany. Methods: A total of 519 RLS patients (mean age: 65.2±11.1 years) in different stages of disease were recruited in five health centres (university hospitals, district hospitals and office-based neurologists) by applying the diagnostic criteria of the International Restless Legs Syndrome Study Group. A questionnaire was administered that assessed healthcare resource consumption as well as socioeconomic, demographic, clinical and health status. In addition, the International RLS severity scale (IRLS), Epworth Sleepiness Scale (ESS), EQ-5D and Beck Depression Inventory (BDI) were addressed in the assessment. Direct and indirect costs (€, year 2006 values) were derived from various German economic resources and calculated from the perspective of the healthcare and transfer payment providers. Results: We calculated average total costs over the 3-month observation period. It was determined that average total costs were €2090 for this period. The average direct medical and non-medical costs from the perspective of the health insurance provider were determined to be €780, with €300 attributed to drug costs and €354 to hospitalization costs. Average total indirect costs amounted to €1308 and were calculated based on productivity loss, using the human capital approach. As cost-driving factors we identified disease severity according to the IRLS (p < 0.01) and ESS (p < 0.04). Health-related quality of life was determined to be substantially affected by RLS; the mean EQ-5D visual analogue scale (VAS) was 55.6, considerably lower than that of the agematched general population. Conclusion: RLS places a notable financial burden on society as well as on patients and their families. More detailed studies are needed to evaluate the health economic impact of this disorder. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
43. Health-related quality of life in patients with Gilles de la Tourette's syndrome.
- Author
-
Müller-Vahl, Kirsten, Dodel, Ines, Müller, Norbert, Münchau, Alexander, Reese, Jens Peter, Balzer-Geldsetzer, Monika, Dodel, Richard, and Oertel, Wolfgang H.
- Abstract
To investigate the health-related quality of life (HrQoL) of adult patients with Gilles de la Tourette's syndrome (GTS) in Germany. HrQoL was evaluated in 200 adult patients with GTS (Mean age: 34.9 ± 11.8 years). Patients were recruited from three outpatient departments in Germany and completed a semi-structured, self-rating interview. HrQoL was measured using the EQ-5D. Depression was assessed using the Beck's depression inventory (BDI) and clinical symptoms using the Yale Tourette syndrome symptom list (TSSL) and the Shapiro Tourette-syndrome severity scale (STSSS). Multivariate regression analyses were performed to identify independent predictors of HrQoL. Patients with GTS proved to have a worse HrQoL than a sample from the general German population. The domains most affected were anxiety/depression (57.1%), followed by pain/discomfort (47.5%), usual activities (38.4%), mobility (14%), and self-care (6.6%). The mean EQ-5D visual analog scale (EQ-VAS) was 65.4 ± 21.9. The patients had a mean BDI score of 12.3 ± 9.9, which was considerably worse compared to a healthy group who had a score of 6.45 ± 5.2. The mean STSSS value was 3.2 ± 1.1. In multivariate analyses, depressive symptoms contributed considerably, whereas the severity of symptoms as well as age only contributed minimally to HrQoL in the model (R
2 = 0.54). HrQoL is considerably reduced in adult patients with GTS. The main independent factors for determining HrQoL were depression, severity of symptoms, and age. Although, treatment of tics is important, co-morbidities such as depression should be diagnosed and treated vigorously. © 2009 Movement Disorder Society [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
44. Evaluation of costs and outcome in cardioembolic stroke or TIA.
- Author
-
Winter, Yaroslav, Wolfram, Caroline, Schaeg, Matthias, Reese, Jens-Peter, Oertel, Wolfgang H., Dodel, Richard, and Back, Tobias
- Subjects
CEREBROVASCULAR disease ,ISCHEMIA ,NEUROLOGY ,ARTERIAL occlusions - Abstract
The costs of acute stroke care, length of hospital stay (LOS), and outcome in patients with cardioembolic stroke or cardioembolic transient ischemic attacks (TIA) were investigated with the aim of estimating the clinical and health-economic impacts of cerebral cardioembolism. The study population consisted of 511 consecutive patients with the diagnosis of ischemic stroke ( n = 379) or TIA ( n = 132) treated at the Department of Neurology, Philipps University, Marburg. Cerebral cardioembolism was defined according to the criteria of the Cerebral Embolism Task Force. Clinical status was assessed by means of Barthel index (BI) and modified Rankin Scale. Costs were calculated using a bottom-up approach. All costs (in Euros) were inflated to the 2008 level. Compared to non-cardioembolic stroke ( n = 278) patients, patients who had suffered cardioembolic stroke ( n = 101) had more severe clinical deficits on admission (BI 46.3 ± 27.0 vs. 59.3 ± 34.1; P < 0.01), worse recovery (BI on discharge 59.2 ± 28.9 vs. 73.1 ± 33.4; P < 0.01), and increased LOS (12.6 ± 5.7 vs. 10.0 ± 7.8 days; P < 0.01). The latter also required a relatively higher daily resource utilization due to increased expenses for personnel and diagnostics. Mean costs of acute care for patients with cardioembolic stroke [€ 4890 per patient (95% confidence interval 4460–5200)] were significantly higher than those for patients with non-cardioembolic stroke [€ 3550 (95% confidence interval 3250–3850); P < 0.01]. The clinical and health-economic impact of cardiogenic cerebral embolism on stroke care is considerable. Patients with cardioembolic stroke/TIA are more severely impaired, and they require longer hospital treatment and increased resource utilization. Costs of acute care of cardioembolic stroke/TIA patients may exceed those of non-cardioembolic stroke/TIA by up to 40%. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
45. Cost of Epilepsy: A Systematic Review.
- Author
-
Strzelczyk, Adam, Reese, Jens Peter, Dodel, Richard, and Hamer, Hajo M.
- Subjects
SYSTEMATIC reviews ,ANTICONVULSANTS ,TREATMENT of epilepsy ,OVERHEAD costs ,METHODOLOGY - Abstract
The objective of this review was to overview published cost-of-illness (COI) studies of epilepsy and their methodological approaches. Epilepsy imposes a substantial burden on individuals and society as a whole. The mean prevalence of epilepsy is estimated at 0.52% in Europe, 0.68% in the US, and peaks up to 1.5% in developing countries. Estimation of the economic burden of epilepsy is of pivotal relevance to enable a rational distribution of healthcare resources. This is especially so with the introduction of the newer antiepileptic drugs (AEDs), the marketing of vagal-nerve stimulators and the resurgence of new surgical treatment options, which have the potential to considerably increase the costs of treating epilepsy. A systematic literature review was performed to identify studies that evaluated direct and indirect costs of epilepsy. Using a standardized assessment form, information on the study design, methodological framework and data sources were extracted from each publication and systematically reported. We identified 22 studies worldwide on costs of epilepsy. The majority of the studies reflected the costs of epilepsy in Europe (three studies each for the UK and Italy, one study each for Germany, the Netherlands, Switzerland, France and the EU) and the US (four studies), but studies were also available from India (two), Hong Kong, Oman, Burundi, Chile and Mexico. The studies utilized different frameworks to evaluate costs. All used a bottom-up approach; however, only 12 studies (55%) evaluated direct as well as indirect costs. The range for the mean annual direct costs lay between 40 International Dollar purchasing power parities (PPP-$) in rural Burundi and PPP-$4748 (adjusted to 2006 values) in a German epilepsy centre. Recent studies suggest AEDs are becoming the main contributor to direct costs. The mean indirect costs ranged between 12% and 85% of the total annual costs. Epilepsy is a cost-intensive disorder. A reliable comparison of the different COI studies in epilepsy is not easily feasible, as the evaluated studies show substantial methodological differences with respect to their patient selection criteria, diagnostic stratifications and evaluated costs. Therefore, there is an urgent need for studies that evaluate direct and indirect costs in a standardized fashion. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
46. Quality Management Systems in the Ambulant Sector: An Analytical Comparison of Different Quality Management Systems.
- Author
-
Gumpert, Marcus and Reese, Jens-Peter
- Published
- 2019
- Full Text
- View/download PDF
47. Preference-based Health status in a German outpatient cohort with multiple sclerosis.
- Author
-
Reese, Jens Peter, Wienemann, Gabriele, John, Axel, Linnemann, Alexandra, Balzer-Geldsetzer, Monika, Mueller, Ulrich Otto, Eienbröker, Christian, Tackenberg, Björn, and Dodel, Richard
- Abstract
Background: To prospectively determine health status and health utility and its predictors in patients with multiple sclerosis (MS).Methods: A total of 144 MS patients (mean age: 41.0 ± 11.3 y) with different subtypes (patterns of progression) and severities of MS were recruited in an outpatient university clinic in Germany. Patients completed a questionnaire at baseline (n = 144), 6 months (n = 65) and 12 months (n = 55). Health utilities were assessed using the EuroQol instrument (EQ-5D, EQ VAS). Health status was assessed by several scales (Expanded Disability Severity Scale (EDSS), Modified Fatigue Impact Scale (M-FIS), Functional Assessment of MS (FAMS), Beck Depression Inventory (BDI-II) and Multiple Sclerosis Functional Composite (MSFC)). Additionally, demographic and socioeconomic parameters were assessed. Multivariate linear and logistic regressions were applied to reveal independent predictors of health status.Results: Health status is substantially diminished in MS patients and the EQ VAS was considerably lower than that of the general German population. No significant change in health-status parameters was observed over a 12-months period. Multivariate analyses revealed M-FIS, BDI-II, MSFC, and EDSS to be significant predictors of reduced health status. Socioeconomic and socio-demographic parameters such as working status, family status, number of household inhabitants, age, and gender did not prove significant in multivariate analyses.Conclusion: MS considerably impairs patients' health status. Guidelines aiming to improve self-reported health status should include treatment options for depression and fatigue. Physicians should be aware of depression and fatigue as co-morbidities. Future studies should consider the minimal clinical difference when health status is a primary outcome. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.